Furthermore, in the case of MODY, we are fortunate to have knowledge that the implicated genetic alteration can guide management (e.g., patients with GCK MODY are generally safe without diabetes treatment and those with HNF1A/HNF4A can often be transitioned from insulin to oral therapy with sulfonylureas) [18]. Here, HNF1A is linked to diabetes mellitus.